Lead
Martine A. Rothblatt, who serves as Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ: UTHR), completed multiple transactions on April 8, 2026, selling a total of 9,139 shares of the company's common stock for an aggregate amount of approximately $5.5 million. The sales occurred across several trades with executed prices ranging from $565.3815 to $585.4782.
Concurrent option exercise
On the same day, Rothblatt exercised stock options to acquire 9,500 shares of United Therapeutics common stock at an exercise price of $146.03 per share, representing a total cash outlay of $1,387,285 for the option exercise.
Post-transaction ownership
Following these actions, Rothblatt's direct ownership in United Therapeutics stands at 40,513 shares. In addition to direct holdings, Rothblatt has indirect interests recorded as 166 shares held by Spouse; 324,518 shares held by Trust; 258,117 shares held by Trust; 45,596 shares held by Trust; and 10,962 shares held by Trust.
Trading plan details
The exercise of stock options and the subsequent sale of the resulting common shares were carried out pursuant to a pre-arranged 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. The plan is structured to continue until the earlier of two possible endpoints - the exercise of 1,734,410 stock options, all of which have an expiration date of March 17, 2027, or December 31, 2026.
Pipeline and regulatory update
In separate corporate developments, United Therapeutics announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to miroliverELAP, an investigational liver device. The device, developed by Miromatrix Medical Inc., a subsidiary of United Therapeutics, is designed to provide temporary liver support for patients with acute liver failure.
Analyst actions following trial data
Several financial firms adjusted their outlooks and price targets on United Therapeutics subsequent to recent trial results. H.C. Wainwright raised its price target to $660 while maintaining a Buy rating and cited positive data from the TETON-1 trial assessing Tyvaso in idiopathic pulmonary fibrosis. Bank of America Securities increased its target to $626 and retained a Neutral rating, citing the same trial data. Jefferies moved its price target to $733, pointing to the strong Phase 3 Tyvaso study results in idiopathic pulmonary fibrosis and noting an increased probability of success for related indications.
Valuation note
According to InvestingPro analysis, United Therapeutics currently appears overvalued relative to its Fair Value. That analysis is presented as a valuation assessment and is accompanied by additional proprietary research materials referenced by the same service covering the company and a broad universe of U.S. equities.
Context and implications
The combination of insider option exercise, share sales under a 10b5-1 plan, regulatory recognition for an investigational device, and upward revisions to analyst price targets captures a clustered set of corporate and market events. The transactions and corporate updates are discrete facts reported by the company and reflected in analyst commentary; they describe recent moves by management, a regulatory designation for a subsidiary-developed device, and shifts in analyst expectations tied to clinical trial outcomes.
Data snapshot
- Shares sold by Rothblatt on April 8, 2026: 9,139
- Approximate proceeds from sales: $5.5 million
- Sale price range: $565.3815 to $585.4782 per share
- Options exercised: 9,500 shares at $146.03 per share (total $1,387,285)
- Direct holdings after transactions: 40,513 shares
- Indirect holdings: 166 (Spouse); 324,518 (Trust); 258,117 (Trust); 45,596 (Trust); 10,962 (Trust)
- 10b5-1 plan adoption date: November 7, 2025
- Plan termination conditions: earlier of exercise of 1,734,410 options (all expire March 17, 2027) or December 31, 2026